Celcuity Inc. (NASDAQ: CELC) soared nearly 46% in early trading on October 20, 2025, after presenting new Phase 3 data at the European Society for Medical Oncology (ESMO) Congress. The sharp rally followed the release of detailed efficacy and safety results from the PIK3CA wild-type cohort of its VIKTORIA-1 trial evaluating gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. At 10:53 a.m. ET, the share price touched USD 75.85, up USD 23.89 from its previous close of USD 51.96.
The data revealed that both gedatolisib-based regimens—one a triplet therapy with fulvestrant and palbociclib, the other a doublet with fulvestrant—produced statistically significant and clinically meaningful progression-free survival (PFS) outcomes. Celcuity Inc., a clinical-stage biotechnology company headquartered in Minneapolis, has now positioned gedatolisib as one of the most promising late-stage investigational agents in endocrine-resistant breast cancer, where treatment options have been limited.
The investor response was immediate, with shares spiking on volume significantly above average as market participants reacted to what analysts framed as a “potential paradigm shift” for patients with PIK3CA wild-type breast cancer who have progressed following treatment with CDK4/6 inhibitors. The presentation was made during a late-breaking oral session at ESMO 2025 in Barcelona and represents the most favorable hazard ratio data reported in this population to date.
What new clinical benchmarks did Celcuity Inc. establish with the gedatolisib regimens in the VIKTORIA-1 trial?
In the PIK3CA wild-type arm of the VIKTORIA-1 trial, the triplet regimen of gedatolisib with palbociclib and fulvestrant achieved a median progression-free survival of 9.3 months compared to 2.0 months with fulvestrant alone. This translates to a 76% reduction in the risk of disease progression or death (hazard ratio: 0.24; 95% confidence interval: 0.17–0.35; p<0.0001). The doublet regimen of gedatolisib with fulvestrant resulted in a median progression-free survival of 7.4 months, a 67% reduction in risk versus fulvestrant (hazard ratio: 0.33; 95% confidence interval: 0.24–0.48; p<0.0001).
Objective response rates were significantly improved as well. The triplet arm posted a 31.5% objective response rate versus just 1% in the control group, while the doublet delivered a 28.3% response rate. The median duration of response was 17.5 months for the triplet regimen and 12.0 months for the doublet, compared to an indeterminable duration for fulvestrant due to a lack of responders.
In patients treated in the United States and Canada, the triplet regimen demonstrated a median progression-free survival of 19.3 months. In this subgroup, the hazard ratio was 0.13, indicating an 87% reduction in risk, while the doublet showed 14.9 months of progression-free survival and a hazard ratio of 0.35.
These outcomes not only surpassed previous Phase 3 results in this setting but also represent the most substantial incremental gains seen with any endocrine therapy-based regimen in patients who have failed prior CDK4/6 inhibitors and aromatase inhibitors.
How are oncology experts interpreting the efficacy of gedatolisib in this advanced breast cancer setting?
The study co-principal investigator, Dr. Sara Hurvitz, who is Senior Vice President of the Clinical Research Division at Fred Hutchinson Cancer Center and Head of Hematology and Oncology at the University of Washington, underscored the significance of the findings. She said that VIKTORIA-1 is the first trial to show a statistically significant and clinically meaningful progression-free survival benefit via inhibition of the PI3K/AKT/mTOR pathway in patients with PIK3CA wild-type disease, all of whom had previously received CDK4/6 inhibitors.
Dr. Hurvitz further emphasized that the consistency of clinical benefit across patient subgroups—including those with endocrine resistance, visceral metastases, and pre/perimenopausal status—positions gedatolisib as a potential new standard of care. The trial’s design allowed for stratification by PIK3CA status, giving Celcuity Inc. clear efficacy readouts in both wild-type and mutant cohorts.
These results mark the first time a pan-PAM pathway inhibitor has succeeded in delivering such durable and broad-spectrum efficacy with manageable toxicity, signaling a potential leap forward in personalized treatment strategies for HR+/HER2- breast cancer.
What are the implications of Celcuity Inc.’s clinical data for investor sentiment and market positioning?
The market’s sharp reaction to the ESMO update reflects investor recognition that Celcuity Inc. has reached an inflection point. Gedatolisib now emerges as a derisked late-stage oncology asset. The stock’s 45.98% intraday gain at USD 75.85 brought Celcuity Inc. back to mid-2021 highs, with trading volume exceeding 10 times its 30-day average.
Institutional sentiment is shifting strongly bullish, with fund managers and life sciences analysts framing the drug as a likely candidate for expedited regulatory review. Celcuity Inc. has already initiated a rolling New Drug Application submission to the U.S. Food and Drug Administration under the agency’s Real-Time Oncology Review program. The company expects to complete this submission in the fourth quarter of 2025.
Investors are now tracking two primary catalysts. The first is the FDA’s decision on the PIK3CA wild-type cohort, which could result in potential approval by mid-2026. The second is the topline readout of the PIK3CA mutant cohort from the same VIKTORIA-1 trial, expected in late Q1 or Q2 2026. If both cohorts demonstrate success, Celcuity Inc. could establish a broad label that would allow penetration into a wide segment of the HR+/HER2- advanced breast cancer market.
How did gedatolisib perform in terms of safety and tolerability, and how does this compare with prior PAM inhibitors?
Historically, therapies targeting the PAM pathway—including PI3K and AKT inhibitors—have shown efficacy at the cost of tolerability, often triggering treatment discontinuations due to side effects such as hyperglycemia, rash, and gastrointestinal toxicity. Gedatolisib, however, demonstrated a substantially more favorable safety profile.
In the VIKTORIA-1 trial, the most common Grade 3 treatment-related adverse events included neutropenia (52.3% in the triplet arm), stomatitis (19.2% in triplet, 12.3% in doublet), rash (4.6% in triplet), and hyperglycemia (2.3% across both gedatolisib regimens). Grade 4 adverse events were limited to neutropenia and leukopenia in the triplet group and pneumonitis in the doublet group, with low incidence.
Importantly, only 2.3% of patients in the triplet group and 3.1% in the doublet group discontinued treatment due to adverse events. This compares favorably to historical data from agents like alpelisib, where treatment discontinuations due to toxicity were notably higher.
Dr. Igor Gorbatchevsky, Chief Medical Officer of Celcuity Inc., stated that the low discontinuation rates and well-tolerated safety profile suggest a strong case for real-world adoption, particularly if the regimen is approved for a population with few good alternatives.
What strategic moves is Celcuity Inc. making to build on the momentum from VIKTORIA-1?
Celcuity Inc. is already executing a multi-pronged strategy to capitalize on the clinical momentum. The company is advancing VIKTORIA-2, a separate Phase 3 study evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line therapy in patients with HR+/HER2- advanced breast cancer. That trial is actively enrolling and is expected to reinforce the case for moving gedatolisib earlier in the treatment sequence.
In parallel, Celcuity Inc. is exploring gedatolisib in metastatic castration-resistant prostate cancer via the CELC-G-201 study, where the drug is being tested in combination with darolutamide. This pipeline-in-a-product approach allows the company to extend its reach beyond breast cancer into other solid tumors where the PAM pathway is implicated in disease progression.
With two fully enrolled pivotal studies and a third in progress, Celcuity Inc. is increasingly seen as a potential takeover target or licensing partner for major oncology players seeking a differentiated asset in the endocrine and hormone-resistant cancer space.
Why does gedatolisib’s mechanism of action matter and how is it differentiated from other targeted therapies?
Gedatolisib’s core innovation lies in its ability to comprehensively inhibit the full PAM signaling axis by targeting all four class I PI3K isoforms, mTORC1, and mTORC2. By contrast, other drugs in this space such as alpelisib or everolimus focus on individual nodes within the pathway. This single-target approach has allowed tumors to develop resistance by activating bypass mechanisms.
Celcuity Inc. has demonstrated in nonclinical studies that gedatolisib maintains cytotoxicity across both PIK3CA wild-type and mutant tumors. This may be due to its pan-inhibitory mechanism, which eliminates escape routes and ensures complete pathway suppression. As such, gedatolisib has the potential to be effective across a broader swath of patients—including those whose tumors have evolved resistance mechanisms not addressed by previous inhibitors.
This mechanistic differentiation, paired with a strong clinical profile and clean safety data, positions gedatolisib as a next-generation therapy that could expand beyond the breast cancer setting.
Key takeaways from Celcuity’s Phase 3 VIKTORIA-1 results and market reaction
- Celcuity Inc. (NASDAQ: CELC) jumped 45.98% to USD 75.85 after presenting VIKTORIA-1 data at ESMO 2025.
- Gedatolisib triplet reduced disease progression risk by 76%; doublet by 67%, vs fulvestrant.
- Median PFS improved by 7.3 months (triplet) and 5.4 months (doublet) over control.
- Consistent benefit seen across subgroups including premenopausal and endocrine-resistant patients.
- Safety profile was manageable; only ~2–3% discontinuation due to adverse events.
- Rolling NDA submission to the FDA has begun under Real-Time Oncology Review pathway.
- Institutional sentiment is strongly bullish with high volume surges seen intraday.
- PIK3CA mutant cohort data expected by Q2 2026; VIKTORIA-2 trial currently enrolling.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
